Overview
- Argentina’s reference lab confirmed three H3N2 subclade K cases—two adolescents in Santa Cruz (one with COVID-19 co-detection) and a hospitalized 5-year-old in Buenos Aires—with genomic sequencing and no reported complications.
- Peru’s health ministry confirmed six H3N2 subclade K cases and reported plans to start 2026 influenza vaccinations with doses arriving in the first half of February.
- Argentina’s latest epidemiological bulletin advises oseltamivir for high-risk and severe cases, emphasizing initiation within 48 hours when possible, permitting later use in severe illness, and urging clinicians not to wait for lab confirmation.
- Officials caution against indiscriminate antiviral use due to resistance risk, noting Malbrán found no rise in oseltamivir-resistant strains in 2024.
- Public guidance reiterates vaccination for priority groups and basic respiratory precautions such as hand hygiene, ventilation, and mask use in crowded settings or when symptomatic, as surveillance tracks the globally expanding H3N2 K lineage.